モダリス turned positive in the afternoon session. The company received a decision to grant a Japanese patent related to muscular dystrophy drug candidate MDL-101, which is expected to strengthen its domestic intellectual property base.
モダリス turned positive in the afternoon session and announced at 11:30 a.m. on the 20th that it had received a decision from the Japan Patent Office to grant a patent for its Japanese patent application related to MDL-101.
The patent is expected to be granted as a Japanese patent after the required procedures are completed, helping strengthen the company’s domestic intellectual property base and protect the future business value of MDL-101.
In the United States, the company is also proceeding with examination of the corresponding patent application under the Patent Prosecution Highway program.